Kushan Gandhi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kushan Gandhi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- John N. J. Reynolds
University of Otago
4 shared publications - Shakila B. Rizwan
School of Pharmacy, University of Otago, Dunedin 9016, New Zealand
4 shared publications - Anita Barzegar-Fallah
Department of Anatomy, School of Biomedical Sciences, University of Otago, Dunedin 9016, New Zealand
3 shared publications - Ashik Banstola
Department of Anatomy, School of Biomedical Sciences, University of Otago, Dunedin 9016, New Zealand
3 shared publications - David H. Bergin
Department of Anatomy, School of Biomedical Sciences University of Otago Dunedin New Zealand
1 shared publication Nicolas Vautrelle
Department of Anatomy, School of Biomedical Sciences University of Otago Dunedin New Zealand
1 shared publication
Latest Publications
- Open Access
- 22 January 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 61 (2) , e16668
Characterising a New Sheep Model of Parkinson's Disease Using Unilateral Intracerebral Injection of 6‐Hydroxydopamine Into the Substantia Nigra
New therapeutic agents developed for treating neurological disorders are often tested successfully on rodents. Testing in an appropriate large animal model where there is longer lifespan and comparable brain size to humans should improve translational success and is frequently expected by regulatory bodies. In this project, we aimed to establish a novel sheep model of Parkinson's disease as a large‐brained experimental model for translational research. Our objective was to create a sheep model of Parkinson's disease by unilaterally infusing the neurotoxin 6‐hydroxydopamine into the substantia nigra pars compacta. This approach, previously used to induce parkinsonism in rat and non‐human primate models, causes dopaminergic imbalance and induces rotational behaviour in quadrupeds challenged with dopaminergic receptor agonists. In the present sheep study, the mixed dopamine receptor agonist apomorphine, 0.25 mg/kg, and dopamine D2 agonist ropinirole, 0.16 mg/kg, were used to induce rotational behaviour and confirm dopamine depletion. Behavioural signs were then measured and characterised in the field using automated movement tracking with simultaneous video recordings. Post‐mortem, the extent of the 6‐hydroxydopamine lesions was evaluated through tyrosine hydroxylase immunohistochemistry and quantifying levels of catecholamines (dopamine, 3,4‐dihydroxyphenylacetic acid and homovanilic acid) quantified using high‐performance liquid chromatography. Our new sheep model of Parkinson's disease using 6‐hydroxydopamine is safe and offers a number of regulatory, ethical and financial advantages over non‐human primate 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine models. It provides a platform to evaluate novel antiparkinsonian agents and medical devices in a large brain with the promise of greater success for translation into clinical application.
- 22 January 2025
- Published by Wiley in European Journal of Neuroscience
- Vol. 61 (2) , e16668
Open AccessCharacterising a New Sheep Model of Parkinson's Disease Using Unilateral Intracerebral Injection of 6‐Hydroxydopamine Into the Substantia Nigra
New therapeutic agents developed for treating neurological disorders are often tested successfully on rodents. Testing in an appropriate large animal model where there is longer lifespan and comparable brain size to humans should improve translational success and is frequently expected by regulatory bodies. In this project, we aimed to establish a novel sheep model of Parkinson's disease as a large‐brained experimental model for translational research. Our objective was to create a sheep model of Parkinson's disease by unilaterally infusing the neurotoxin 6‐hydroxydopamine into the substantia nigra pars compacta. This approach, previously used to induce parkinsonism in rat and non‐human primate models, causes dopaminergic imbalance and induces rotational behaviour in quadrupeds challenged with dopaminergic receptor agonists. In the present sheep study, the mixed dopamine receptor agonist apomorphine, 0.25 mg/kg, and dopamine D2 agonist ropinirole, 0.16 mg/kg, were used to induce rotational behaviour and confirm dopamine depletion. Behavioural signs were then measured and characterised in the field using automated movement tracking with simultaneous video recordings. Post‐mortem, the extent of the 6‐hydroxydopamine lesions was evaluated through tyrosine hydroxylase immunohistochemistry and quantifying levels of catecholamines (dopamine, 3,4‐dihydroxyphenylacetic acid and homovanilic acid) quantified using high‐performance liquid chromatography. Our new sheep model of Parkinson's disease using 6‐hydroxydopamine is safe and offers a number of regulatory, ethical and financial advantages over non‐human primate 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine models. It provides a platform to evaluate novel antiparkinsonian agents and medical devices in a large brain with the promise of greater success for translation into clinical application.
- Open Access
- 20 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 5
Correction: Gandhi et al. Ultrasound-Mediated Blood–Brain Barrier Disruption for Drug Delivery: A Systematic Review of Protocols, Efficacy, and Safety Outcomes from Preclinical and Clinical Studies. Pharmaceutics 2022, 14, 833
- 20 December 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 5
Open AccessCorrection: Gandhi et al. Ultrasound-Mediated Blood–Brain Barrier Disruption for Drug Delivery: A Systematic Review of Protocols, Efficacy, and Safety Outcomes from Preclinical and Clinical Studies. Pharmaceutics 2022, 14, 833
- Open Access
- 19 October 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (10) , 2231
Harnessing Ultrasound for Targeting Drug Delivery to the Brain and Breaching the Blood–Brain Tumour Barrier
Despite significant advances in developing drugs to treat brain tumours, achieving therapeutic concentrations of the drug at the tumour site remains a major challenge due to the presence of the blood–brain barrier (BBB). Several strategies have evolved to enhance brain delivery of chemotherapeutic agents to treat tumours; however, most approaches have several limitations which hinder their clinical utility. Promising studies indicate that ultrasound can penetrate the skull to target specific brain regions and transiently open the BBB, safely and reversibly, with a high degree of spatial and temporal specificity. In this review, we initially describe the basics of therapeutic ultrasound, then detail ultrasound-based drug delivery strategies to the brain and the mechanisms by which ultrasound can improve brain tumour therapy. We review pre-clinical and clinical findings from ultrasound-mediated BBB opening and drug delivery studies and outline current therapeutic ultrasound devices and technologies designed for this purpose.
- 19 October 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (10) , 2231
Open AccessHarnessing Ultrasound for Targeting Drug Delivery to the Brain and Breaching the Blood–Brain Tumour Barrier
Despite significant advances in developing drugs to treat brain tumours, achieving therapeutic concentrations of the drug at the tumour site remains a major challenge due to the presence of the blood–brain barrier (BBB). Several strategies have evolved to enhance brain delivery of chemotherapeutic agents to treat tumours; however, most approaches have several limitations which hinder their clinical utility. Promising studies indicate that ultrasound can penetrate the skull to target specific brain regions and transiently open the BBB, safely and reversibly, with a high degree of spatial and temporal specificity. In this review, we initially describe the basics of therapeutic ultrasound, then detail ultrasound-based drug delivery strategies to the brain and the mechanisms by which ultrasound can improve brain tumour therapy. We review pre-clinical and clinical findings from ultrasound-mediated BBB opening and drug delivery studies and outline current therapeutic ultrasound devices and technologies designed for this purpose.
- Open Access
- 11 April 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (4) , 833
Ultrasound-Mediated Blood–Brain Barrier Disruption for Drug Delivery: A Systematic Review of Protocols, Efficacy, and Safety Outcomes from Preclinical and Clinical Studies
Ultrasound-mediated blood–brain barrier (BBB) disruption has garnered focus as a method of delivering normally impenetrable drugs into the brain. Numerous studies have investigated this approach, and a diverse set of ultrasound parameters appear to influence the efficacy and safety of this approach. An understanding of these findings is essential for safe and reproducible BBB disruption, as well as in identifying the limitations and gaps for further advancement of this drug delivery approach. We aimed to collate and summarise protocols and parameters for achieving ultrasound-mediated BBB disruption in animal and clinical studies, as well as the efficacy and safety methods and outcomes associated with each. A systematic search of electronic databases helped in identifying relevant, included studies. Reference lists of included studies were further screened to identify supplemental studies for inclusion. In total, 107 articles were included in this review, and the following parameters were identified as influencing efficacy and safety outcomes: microbubbles, transducer frequency, peak-negative pressure, pulse characteristics, and the dosing of ultrasound applications. Current protocols and parameters achieving ultrasound-mediated BBB disruption, as well as their associated efficacy and safety outcomes, are identified and summarised. Greater standardisation of protocols and parameters in future preclinical and clinical studies is required to inform robust clinical translation.
- 11 April 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (4) , 833
Open AccessUltrasound-Mediated Blood–Brain Barrier Disruption for Drug Delivery: A Systematic Review of Protocols, Efficacy, and Safety Outcomes from Preclinical and Clinical Studies
Ultrasound-mediated blood–brain barrier (BBB) disruption has garnered focus as a method of delivering normally impenetrable drugs into the brain. Numerous studies have investigated this approach, and a diverse set of ultrasound parameters appear to influence the efficacy and safety of this approach. An understanding of these findings is essential for safe and reproducible BBB disruption, as well as in identifying the limitations and gaps for further advancement of this drug delivery approach. We aimed to collate and summarise protocols and parameters for achieving ultrasound-mediated BBB disruption in animal and clinical studies, as well as the efficacy and safety methods and outcomes associated with each. A systematic search of electronic databases helped in identifying relevant, included studies. Reference lists of included studies were further screened to identify supplemental studies for inclusion. In total, 107 articles were included in this review, and the following parameters were identified as influencing efficacy and safety outcomes: microbubbles, transducer frequency, peak-negative pressure, pulse characteristics, and the dosing of ultrasound applications. Current protocols and parameters achieving ultrasound-mediated BBB disruption, as well as their associated efficacy and safety outcomes, are identified and summarised. Greater standardisation of protocols and parameters in future preclinical and clinical studies is required to inform robust clinical translation.